Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer

INTRODUCTION: MUC1 is a cell-surface glycoprotein that establishes a molecular barrier at the epithelial surface and engages in morphogenetic signal transduction. Alterations in MUC1 glycosylation accompany the development of cancer and influence cellular growth, differentiation, transformation, adh...

Descripción completa

Detalles Bibliográficos
Autores principales: Pegram, Mark D, Borges, Virginia F, Ibrahim, Nuhad, Fuloria, Jyotsna, Shapiro, Charles, Perez, Susan, Wang, Karen, Schaedli Stark, Franziska, Courtenay Luck, Nigel
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790853/
https://www.ncbi.nlm.nih.gov/pubmed/19811637
http://dx.doi.org/10.1186/bcr2409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790853/
https://www.ncbi.nlm.nih.gov/pubmed/19811637
http://dx.doi.org/10.1186/bcr2409

Ejemplares similares